
Andrea K. Mccollum
Examiner (ID: 11971, Phone: (571)272-4002 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1674, 1646 |
| Total Applications | 733 |
| Issued Applications | 360 |
| Pending Applications | 111 |
| Abandoned Applications | 301 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 12322875
[patent_doc_number] => 09943600
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-04-17
[patent_title] => Stabilizing agent for pharmaceutical proteins
[patent_app_type] => utility
[patent_app_number] => 14/245252
[patent_app_country] => US
[patent_app_date] => 2014-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4787
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14245252
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/245252 | Stabilizing agent for pharmaceutical proteins | Apr 3, 2014 | Issued |
Array
(
[id] => 11487102
[patent_doc_number] => 09593166
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-03-14
[patent_title] => 'Monoclonal antibodies against antithrombin β'
[patent_app_type] => utility
[patent_app_number] => 14/214382
[patent_app_country] => US
[patent_app_date] => 2014-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 29
[patent_no_of_words] => 13085
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14214382
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/214382 | Monoclonal antibodies against antithrombin β | Mar 13, 2014 | Issued |
Array
(
[id] => 9735826
[patent_doc_number] => 20140271538
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients'
[patent_app_type] => utility
[patent_app_number] => 14/213989
[patent_app_country] => US
[patent_app_date] => 2014-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 33822
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14213989
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/213989 | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients | Mar 13, 2014 | Abandoned |
Array
(
[id] => 14055483
[patent_doc_number] => 10232018
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-19
[patent_title] => ACTH for treatment of acute respiratory distress syndrome
[patent_app_type] => utility
[patent_app_number] => 14/214449
[patent_app_country] => US
[patent_app_date] => 2014-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 22879
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14214449
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/214449 | ACTH for treatment of acute respiratory distress syndrome | Mar 13, 2014 | Issued |
Array
(
[id] => 10679572
[patent_doc_number] => 20160025717
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-28
[patent_title] => 'HYPOSIALYLATION DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 14/775507
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 20500
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14775507
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/775507 | HYPOSIALYLATION DISORDERS | Mar 12, 2014 | Abandoned |
Array
(
[id] => 9735903
[patent_doc_number] => 20140271615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'HYPOSIALYLATION DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 14/208570
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 19961
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14208570
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/208570 | Hyposialylation disorders | Mar 12, 2014 | Issued |
Array
(
[id] => 9735916
[patent_doc_number] => 20140271628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'HUMANIZED, ANTI-N2 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 14/206368
[patent_app_country] => US
[patent_app_date] => 2014-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14770
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14206368
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/206368 | Humanized, anti-N2 antibodies | Mar 11, 2014 | Issued |
Array
(
[id] => 10573102
[patent_doc_number] => 09295724
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-03-29
[patent_title] => 'Stable formulations for parenteral injection of peptide drugs'
[patent_app_type] => utility
[patent_app_number] => 14/192679
[patent_app_country] => US
[patent_app_date] => 2014-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 19658
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14192679
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/192679 | Stable formulations for parenteral injection of peptide drugs | Feb 26, 2014 | Issued |
Array
(
[id] => 10620617
[patent_doc_number] => 09339545
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-05-17
[patent_title] => 'Stable formulations for parenteral injection of peptide drugs'
[patent_app_type] => utility
[patent_app_number] => 14/192697
[patent_app_country] => US
[patent_app_date] => 2014-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 19618
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14192697
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/192697 | Stable formulations for parenteral injection of peptide drugs | Feb 26, 2014 | Issued |
Array
(
[id] => 10579898
[patent_doc_number] => 09302010
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-04-05
[patent_title] => 'Stable formulations for parenteral injection of peptide drugs'
[patent_app_type] => utility
[patent_app_number] => 14/188464
[patent_app_country] => US
[patent_app_date] => 2014-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 19617
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14188464
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/188464 | Stable formulations for parenteral injection of peptide drugs | Feb 23, 2014 | Issued |
Array
(
[id] => 9670998
[patent_doc_number] => 20140234861
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-21
[patent_title] => 'METHOD FOR DIAGNOSIS, PROGNOSIS OR TREATMENT OF ACUTE CORONARY SYNDROME (ACS) COMPRISING MEASUREMENT OF PLASMA CONCENTRATION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)'
[patent_app_type] => utility
[patent_app_number] => 14/178660
[patent_app_country] => US
[patent_app_date] => 2014-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 9948
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14178660
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/178660 | Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF) | Feb 11, 2014 | Issued |
Array
(
[id] => 9615755
[patent_doc_number] => 20140205613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-24
[patent_title] => 'ANTI-TNF AND ANTI-IL 17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE'
[patent_app_type] => utility
[patent_app_number] => 14/160253
[patent_app_country] => US
[patent_app_date] => 2014-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 17089
[patent_no_of_claims] => 96
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14160253
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/160253 | ANTI-TNF AND ANTI-IL 17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE | Jan 20, 2014 | Abandoned |
Array
(
[id] => 9511891
[patent_doc_number] => 20140148383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-05-29
[patent_title] => 'Entacapone for prevention and treatment of obesity and related metabolic diseases'
[patent_app_type] => utility
[patent_app_number] => 14/147531
[patent_app_country] => US
[patent_app_date] => 2014-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 4330
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14147531
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/147531 | Entacapone for prevention and treatment of atherosclerosis | Jan 3, 2014 | Issued |
Array
(
[id] => 9560682
[patent_doc_number] => 20140178395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-26
[patent_title] => 'TREATMENT OF NEPHROPATHY'
[patent_app_type] => utility
[patent_app_number] => 14/135921
[patent_app_country] => US
[patent_app_date] => 2013-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 9738
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14135921
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/135921 | TREATMENT OF NEPHROPATHY | Dec 19, 2013 | Abandoned |
Array
(
[id] => 9634323
[patent_doc_number] => 20140212431
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-31
[patent_title] => 'PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 14/133986
[patent_app_country] => US
[patent_app_date] => 2013-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 13379
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14133986
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/133986 | PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE | Dec 18, 2013 | Abandoned |
Array
(
[id] => 9546975
[patent_doc_number] => 20140171624
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-19
[patent_title] => 'MODULATORS OF ADP-DEPENDENT GLUCOKINASE (ADPGK) AND GLYCEROL-3-PHOSPHATE DEHYDROGENASE (GPD2) FOR THERAPY'
[patent_app_type] => utility
[patent_app_number] => 14/099466
[patent_app_country] => US
[patent_app_date] => 2013-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 16475
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14099466
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/099466 | MODULATORS OF ADP-DEPENDENT GLUCOKINASE (ADPGK) AND GLYCEROL-3-PHOSPHATE DEHYDROGENASE (GPD2) FOR THERAPY | Dec 5, 2013 | Abandoned |
Array
(
[id] => 9517770
[patent_doc_number] => 20140154263
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-05
[patent_title] => 'Use of TAK1 Inhibitor to Achieve Glycemic Control in Mammals'
[patent_app_type] => utility
[patent_app_number] => 14/097967
[patent_app_country] => US
[patent_app_date] => 2013-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 5779
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14097967
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/097967 | Use of TAK1 Inhibitor to Achieve Glycemic Control in Mammals | Dec 4, 2013 | Abandoned |
Array
(
[id] => 10946294
[patent_doc_number] => 20140349316
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-11-27
[patent_title] => 'USE OF TUMOR NECROSIS FACTOR (TNF) RECEPTOR-ASSOCIATED FACTOR 7 (TRAF7) AS BIOMARKER FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), METHOD AND KIT FOR DETECTING OF HUMAN WITH SLE'
[patent_app_type] => utility
[patent_app_number] => 14/091325
[patent_app_country] => US
[patent_app_date] => 2013-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 2728
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14091325
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/091325 | USE OF TUMOR NECROSIS FACTOR (TNF) RECEPTOR-ASSOCIATED FACTOR 7 (TRAF7) AS BIOMARKER FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), METHOD AND KIT FOR DETECTING OF HUMAN WITH SLE | Nov 25, 2013 | Abandoned |
Array
(
[id] => 10149260
[patent_doc_number] => 09181538
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2015-11-10
[patent_title] => 'Kexin-based vaccines to prevent or treat fungal infections'
[patent_app_type] => utility
[patent_app_number] => 14/088250
[patent_app_country] => US
[patent_app_date] => 2013-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 21708
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14088250
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/088250 | Kexin-based vaccines to prevent or treat fungal infections | Nov 21, 2013 | Issued |
Array
(
[id] => 9369846
[patent_doc_number] => 20140079719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-03-20
[patent_title] => 'IL-17 Antagonistic Antibodies'
[patent_app_type] => utility
[patent_app_number] => 14/085074
[patent_app_country] => US
[patent_app_date] => 2013-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 19088
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14085074
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/085074 | IL-17 Antagonistic Antibodies | Nov 19, 2013 | Abandoned |